Three vaccine candidates are racing toward human trials as researchers in Oxford, Moderna's laboratories, and the International AIDS Vaccine Initiative (IAVI) work urgently to develop the first countermeasures against the Bundibugyo virus outbreak spreading across the Democratic Republic of Congo. The World Health Organization has declared this outbreak a public health emergency of international concern, and the speed of vaccine development may determine whether communities across Central Africa can contain a disease for which no approved treatments exist.
The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged $62 million to fast-track these three investigational candidates, recognizing that time is the scarcest resource in an epidemic. Initial vaccine doses could be ready for human testing within two to three months, though the most promising candidate—developed by IAVI and the University of Texas Medical Branch—may require seven to nine months before it advances to clinical trials. Teresa Lambe, head of vaccine immunology at the Oxford Vaccine Group, explains that scientists are applying hard-won lessons from COVID-19 vaccine development to compress timelines without cutting corners on safety. "Animal studies for the Oxford vaccine candidate are already under way and will be progressing with partners around the world," Lambe said. "We are hoping to have clinical-grade vaccine doses ready within two to three months."
The outbreak's toll is climbing rapidly. As of late May, 223 suspected deaths had been recorded in the DRC, with additional cases confirmed in Uganda, where six new cases emerged in early June, bringing the country's confirmed total to 15. Africa CDC head Jean Kaseya has identified 11 high-risk countries vulnerable to cross-border spread due to population movement, including South Sudan, Somalia, Rwanda, Kenya, Tanzania, Ethiopia, the Republic of Congo, Burundi, Angola, the Central African Republic, and Zambia. The African Union health agency has developed a continent-wide response plan requiring $319 million over the next six months to strengthen outbreak control across these vulnerable nations.
International funding is mobilizing at an unprecedented scale. Gavi, the Vaccine Alliance, has committed $50 million to the outbreak response through its First Response Fund, with up to $40 million dedicated to accelerating vaccine access once candidates are approved. The Oxford vaccine will be manufactured at the Serum Institute of India, positioning a crucial supply chain to deliver doses at scale to African nations. Jean Kaseya has promised that Africa will have vaccines and treatments "by the end of this year"—a bold commitment reflecting both urgency and the genuine acceleration made possible by parallel development pathways and pre-positioned manufacturing capacity.
What distinguishes this response is the deliberate architecture built to prevent the delays that have plagued past outbreaks. CEPI Chief Executive Richard Hatchett noted that "every day counts in the race against this deadly disease," yet the funding and coordination announced suggests Africa's health systems are moving faster than ever before. The three vaccine developers—spanning academic institutions, American biotech, and global initiatives—are working simultaneously rather than sequentially, and manufacturers are being positioned to begin production before efficacy data arrives, eliminating months typically lost to preparation.
Experts warn, however, that response efforts are still struggling to keep pace with the outbreak's spread. The next six months will test whether this accelerated vaccine development succeeds before the virus establishes itself across multiple countries, and whether the promised manufacturing and distribution capacity can deliver doses to vulnerable populations faster than the virus spreads.